Table 4.
Clinical inertia in total patient population and by age subgroup
| Clinical inertia | Age subgroups | Total patient population (N = 2709; 100%) | |
|---|---|---|---|
| 30–64 years (n = 1214; 44.8%) | ≥ 65 years (n = 1495; 55.2%) | ||
| Patients without intensification at the end of follow-up (n = 606) according to HbAc1 range, % (95% CI) | 20.2% (17.9–22.5%) | 24.1% (21.8–26.4%) | 22.4% (20.8–24.0%) |
| HbA1c 8.0–8.9% | 23.4% (20.0–25.8%) | 25.8% (23.3–28.3%) | 24.6% (23.0–26.2%) |
| HbA1c 9.0–9.9% | 20.5% (18.2–22.8%) | 21.7% (19.4–24.0%) | 21.1% (19.6–22.6%) |
| HbA1c ≥ 10.0% | 13.6% (11.7–15.5%) | 20.5% (18.4–22.6%) | 17.1% (15.7–18.5%) |
| Patients without intensification at various time points during follow-up, % (95% CI) | |||
| 6 months | 78.4% (76.1–80.7%) | 77.4% (75.3–79.5%) | 77.8% (76.2–79.4%) |
| 1 year | 58.3% (55.5–61.1%) | 60.6% (58.1–63.1%) | 59.5% (57.6–61.4%) |
| 2 years | 41.3% (38.5–44.1%) | 41.7% (39.2–44.2%) | 41.5% (39.6–43.4%) |
| 3 years | 26.1% (23.6–28.6%) | 29.7% (27.4–32.0%) | 28.1% (26.4–29.8%) |
| Time to first intensification, days | |||
| Mean (SD) | 460.8 (394.2) | 516.1 (446.0) | 490.6 (423.7) |
| Median (95% CI) | 422 (394–450) | 485 (460–510) | 456 (429–483) |
| HbA1c 8.0–8.9%, median (95% CI) | 436 (408–464) | 493 (468–518) | 495 (480–518) |
| HbA1c 9.0–9.9%, median (95% CI) | 427 (399–455) | 484 (459–509) | 457 (438–476) |
| HbA1c ≥ 10.0%, median (95% CI) | 403 (375–431) | 472 (447–497) | 388 (370–406) |
| Time to administration of GLP-1 RA/insulin, days | |||
| Mean (SD) | 878.6 (630.3) | 1082.8 (631.5) | 962.2 (637.7) |
| Median (95% CI) | 783 (761–805) | 1055 (1029–1081) | 854 (827–881) |
| HbA1c 8.0–8.9%, median (95% CI) | 840 (820–860) | 1178 (1152–1204) | 912 (885–939) |
| HbA1c 9.0–9.9%, median (95% CI) | 648 (622–674) | 991 (965–1017) | 766 (739–793) |
| HbA1c ≥ 10.0%, median (95% CI) | 610 (583–637) | 905 (879–931) | 730 (703–757) |
| Patients administered GLP-1 RA/insulin, % (95% CI) | 31.6% (29.0–34.2%) | 38.3% (35.8–40.8%) | 34.8% (33.0–36.6%) |
| HbA1c 8.0–8.9% | 16.5% (14.4–18.6%) | 11.5% (9.9–13.1%) | 14.2% (12.9–15.5%) |
| HbA1c 9.0–9.9% | 38.3% (35.6–41.0%) | 40.2% (37.7–42.7%) | 39.2% (37.4–41.0%) |
| HbA1c ≥ 10.0% | 45.2% (42.4–48.0%) | 48.3% (45.8–50.8%) | 46.6% (44.7–48.5%) |
| Mean number of intensifications per patient during study period (N = 2103), HbA1c ≥ 8% | 1.4 (0.6; 1.3–1.5) | 1.5 (0.6; 1.4–1.6) | 1.4 (0.6; 1.3–1.5) |
| HbA1c 8.0–8.9% (SD; 95% CI) | 1.1 (0.3; 1.0–1.2) | 1.2 (0.5; 1.1–1.3) | 1.2 (0.4; 1.1–1.3) |
| HbA1c 9.0–9.9% (SD; 95% CI) | 1.3 (0.5; 1.2–1.4) | 1.4 (0.5; 1.3–1.5) | 1.4 (0.5; 1.3–1.5) |
| HbA1c ≥ 10.0% (SD; 95% CI) | 1.8 (0.8; 1.7–1.9) | 2.0 (0.8; 1.9–2.1) | 1.9 (0.8; 1.8–2.0) |
| Treatment addition* (95% CI) | 33.0% (30.4–35.6%) | 34.4% (32.0–36.8%) | 33.8% (32.0–35.6) |
| Treatment change* (95% CI) | 65.7% (63.0–68.4) | 64.9% (62.5–67.3%) | 65.3% (63.5–67.1%) |
| Increased dose* (95% CI) | 1.2% (0.6–1.8%) | 0.7% (0.3–1.1%) | 1.0% (0.8–1.3%) |
HbA1c glycosylated haemoglobin (%), GLP-1 glucagon-like peptide type 1
Values expressed as percentages, mean (SD: standard deviation), 95%CI: confidence interval
p statistical significance* percentages refer to total intensifications